FDA- No Questions On GRAS Status For Enzymotec's Phosphatidylserine

Enzymotec announces that it had received "No Questions" from the US-FDA for its GRAS notification on Sharp-PSTM (Phosphatidylserine) product .

Enzymotec expects to publish the results of three human clinical trials made on Phosphatidylserine (PS) in the next few months.

PS, is a common dietary supplement used to improve memory, concentration and other cognitive capabilities, especially for the aged population.

"We believe that PS can expand into functional foods in the near future and a GRAS determination was the first step to enable that. We have already tested its applicability into chocolate bars and dairy applications with great feedback on taste and texture." says, Mrs. Iris Meiri-Benedek, Enzymotec regulatory affairs manager. "What makes this product unique is the fact that it is GRAS for use in its active dosages that will allow functional food manufacturers to introduce an efficacious level of PS in their finished products, thus extending their flexibility and the message they will eventually be able to make for their products" concludes Mrs. Meiri-Benedek.

Enzymotec is an Israeli biotech company, that develops and produces novel ,lipid-based health ingredients for dietary supplements and functional foods.

The company's leading products are:, SharpPSTM and SharpPSTM GOLD for cognitive performance improvement of seniors , CardiaBeatTM offering a broad health effect to reduce CVD risks and InFatTM for balanced nutrition in infant formula.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.